REVIEW ARTICLE

Nagoya J. Med. Sci. **85**. 35–49, 2023 doi:10.18999/nagjms.85.1.35

A systematic review regarding clinical characteristics, complications, and outcomes of surgical and non-surgical patients with fragility fracture of the pelvis

Takaomi Kobayashi^{1,2}, Takayuki Akiyama^{1,2}, Tadatsugu Morimoto^{1,2}, Kensuke Hotta³ and Masaaki Mawatari^{1,2}

¹Department of Orthopaedic Surgery, Imari-Arita Kyoritsu Hospital, Arita, Japan ²Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan ³Department of Orthopaedic Surgery, Amagi Chuo Hospital, Asakura, Japan

ABSTRACT

We conducted this systematic review to clarify the clinical characteristics, complications, and outcomes of surgical and non-surgical patients with fragility fracture of the pelvis (FFP). We searched PubMed, Google Scholar, Cochrane Library, Web of Science, and MEDLINE for English language articles on FFP. We calculated pooled odds ratios (ORs) or mean differences (MDs) of surgical patients in comparison to non-surgical patients for clinical characteristics (Rommens FFP classification, age, sex, dementia, osteoporosis, diabetes mellitus, pulmonary disease, cardiovascular disease, and malignancy), complications (pneumonia, urinary tract infection, cardiac event, thrombosis, pulmonary embolism, pressure ulcer, multiple organ failure, anemia caused by surgical bleeding, and surgical site infection), and outcomes (hospital mortality and one-year mortality). Five studies involving 1,090 patients with FFP (surgical patients, n = 432; non-surgical patients, n = 658) were included. FFP type III and IV (OR = 8.44; 95% confidence interval [CI] 5.99 to 11.88; p < 0.00001), a younger age (MD=-3.29; 95% CI -3.83 to -2.75; p < 0.00001), the absence of dementia (OR=0.36; 95% CI 0.23 to 0.57; p < 0.0001), and the presence of osteoporosis (OR=1.74; 95% CI 1.29 to 2.35; p=0.0003) were significantly associated with the surgical patients. Urinary tract infection (OR=2.06; 95% CI 1.37 to 3.10; p=0.0005), anemia caused by surgical bleeding (OR=4.55; 95% CI 1.95 to 10.62; p = 0.0005), and surgical site infection (OR=16.74; 95% CI 3.05 to 91.87; p = 0.001) were significantly associated with the surgical patients. There were no significant differences in the outcomes between the surgical and non-surgical patients. Our findings may help to further understand the treatment strategy for FFP and improve clinical outcomes.

Keywords: fragility fracture of the pelvis, review, complication, mobility, surgery

Abbreviations: FFP: fragility fracture of the pelvis OR: odds ratio MD: mean difference CI: confidence interval PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Received: December 15, 2021; accepted: March 30, 2022

Corresponding Author: Takaomi Kobayashi, MD

Department of Orthopaedic Surgery, Imari-Arita Kyoritsu Hospital,

860 Ninosekou, Arita-cho, Nishimatsuura-gun, Saga 849-4141, Japan

TEL: +81-955-46-2121, Fax: +81-955-46-2123, E-mail: m10036tk@jichi.ac.jp

INTRODUCTION

Fragility fracture of the pelvis (FFP) is a common injury caused by low-energy trauma (eg, fall from standing height or lower) in the elderly with loss of bone mineral density.¹⁻⁶ The prevalence has been rising with the aging of the world's population.⁷⁻⁹ Nevertheless, the treatment strategy for FFP remains the subject of ongoing debate.¹⁰⁻¹⁸ Rommens et al¹⁰⁻¹³ recently developed a radiographic classification of FFP and a management protocol (Fig. 1): conservative therapy is efficacious for FFP types I (anterior lesions only) and II (non-displaced posterior lesions). If conservative therapy fails after days or weeks in FFP type I, magnetic resonance imaging is performed to rule out occult sacral fractures. If conservative therapy fails within days in FFP type II, surgical stabilization is recommended. In contrast, surgical stabilization is recommended for FFP types III (displaced unilateral posterior lesions) and IV (displaced bilateral posterior lesions). Surgery is performed after obtaining written informed consent from the patient or their relatives in all cases. This treatment strategy is one of the most commonly applied classifications and management protocols for FFP.¹⁰⁻¹⁸ To further understand the treatment strategy of FFP described by Rommens et al¹⁰⁻¹³ and to improve the clinical outcomes, the clinical characteristics,




Fig. 1 Rommens classification of fragility fractures of the pelvis $(FFP)^{10\text{--}13}$

FFP type Ia: unilateral anterior pelvic ring disruption

FFP type Ib: bilateral anterior pelvic ring disruption

FFP type IIa: dorsal non-displaced posterior injury only

FFP type IIb: sacral crush with anterior disruption

FFP type IIc: non-displaced sacral, sacroiliac, or iliac fracture with anterior disruption

FFP type IIIa: displaced unilateral iliac fracture and anterior disruption

FFP type IIIb: displaced unilateral sacroiliac disruption and anterior disruption

FFP type IIIc: displaced unilateral sacral fracture together with anterior disruption

FFP type IVa: bilateral iliac fractures or bilateral sacroiliac disruptions together with anterior disruption

FFP type IVb: spinopelvic dissociation together with anterior disruption

FFP type IVc: combination of various posterior instabilities together with anterior disruption

The reproduction of this figure is permitted by Springer Nature (License Number: 5243010021188).

Nagoya J. Med. Sci. 85. 35-49, 2023

complications, and outcomes of surgical and non-surgical patients with FFP should be clarified.¹⁶⁻²⁴ We therefore conducted the present systematic review.

MATERIALS AND METHODS

Search strategy and criteria

The protocol of the systematic review was registered at the International Prospective Register of Systematic Reviews (PROSPERO registration no. CRD42021276549). This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.^{25,26} PubMed, Google Scholar, Cochrane Library, Web of Science, and MEDLINE were searched for relevant English language articles that compared the clinical characteristics, complications, and outcomes between surgical and non-surgical FFP patients, who were treated according to the strategy described by Rommens et al.¹⁰⁻¹³ All searches were conducted on November 1, 2021. The search terms used in PubMed were as follows: (fragility fracture[Title/Abstract]) OR (osteoporotic fracture[Title/Abstract]) AND (pelvis[Title/Abstract]). The other databases were searched using similar search strategies. We excluded articles that did not investigate this topic, as well as review articles, case reports (n<3), commentaries, editorials, insights articles, and proceedings. We searched for unpublished or gray literature in this systematic review. We screened websites, organizations, or the reference lists of records identified through the database search. Two researchers (TK and TA) independently evaluated the eligibility of retrieved articles and any disagreements were resolved based on a discussion. No ethics committee or institutional review board approval was required for this systematic review.

Quality assessment

Quality assessment was performed according to the Newcastle–Ottawa Scale,²⁷ as the eligible studies were not randomized trials (prospective or retrospective cohort studies). Two researchers (TK and TA) independently screened the extracted literature and extracted the data to ensure the consistency of the results; any disagreements were resolved with a discussion.

Data extraction

The following data were extracted: first author, publication year, study type, patient (ie, number of patients, Rommens FFP classification,¹⁰⁻¹³ age, and sex), surgical patients (ie, number of patients, age, sex, and surgical treatment), non-surgical patients (ie, number of patients, age, sex), clinical characteristics (ie, Rommens FFP classification, age, sex, dementia, osteoporosis, diabetes mellitus, pulmonary disease, cardiovascular disease, and malignancy), complications (ie, pneumonia, urinary tract infection, cardiac event, thrombosis, pulmonary embolism, pressure ulcer, multiple organ failure, anemia caused by surgical bleeding, and surgical site infection), and outcomes (hospital mortality and one-year mortality). Two researchers (TK and TA) independently extracted the data.

Data analysis and statistical methods

This systematic review was performed using the Review Manager software program (version 5.3; The Cochrane Collaboration, Oxford, United Kingdom). The number of events was entered for binary variables and the number of subjects, as well as the mean value and standard deviation of continuous variables and the number of subjects. The X^2 test and I^2 statistic were performed to assess the heterogeneity level: insignificant ($I^2 0\%$ to <25%), low ($I^2 25\%$ to <50%), and significant ($I^2 50-100\%$). If significant heterogeneity was observed (p<0.10 and $I^2>50\%$), a random-effects model was used for the analysis. Otherwise, a fixed-effects model was used.

Binary variables were evaluated using odds ratios (ORs) with 95% confidence intervals (CIs). Continuous variables were evaluated using mean difference (MDs) with 95% CIs. P values of <0.05 were considered to indicate statistical significance. One researcher (TK) performed all of the statistical analyses.

RESULTS

Search results

Figure 2 shows the PRISMA flow chart for our systematic review. The initial database search identified 376 records. After screening, 7 records underwent full-text review. Two full-text records




Fig. 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart describing article selection

			Table 1 Summ	Summary of selected studies			
Author, Year	Study design	Patient	Surgical patient	Non-surgical patient	Characteristic	Complication	Outcome
Oberkircher et al, 2021 ²⁰	Prospective	FFP, 134 (type I, 41; type II, 81; type II, 10; type IV, 2) Age (years), 79.9 ± 7.7 Gender (men/women), 52/82	Surgical treatment, 48 (percutaneous surgery, 35; ORIF, 13) Age (years), 78.5 ± 7.0 Gender (men/women), N/A	Non-surgical treatment, 86 Age (years), 80.7 ± 7.6 Gender (men/women), N/A	Rommens FFP classification and age	Pneumonia, urinary tract infection, cardiac event, pulmonary embolism, multiple organ failure, anemia caused by surgical bleeding, and surgical site infection	Hospital mortality
Gericke et al, 2021 ²¹	Retrospective	FFP, 379 (type I, 56; type II, 200; type III, 58; type IV, 65) Age (years), 81.3 ± 7.5 Gender (men/women), 74/305	Surgical treatment, 168 (percutaneous surgery, 74; ORIF, 94) Age (years), 79,4 ± 6.6 Gender (men/women), 38/130	Non-surgical treatment, 211 Age (years), 82.8 ± 7.8 Gender (men/women), 36/175	Rommens FFP clas- sification, age, sex, dementia, osteoporosis, diabetes mellitus, pulmonary disease, cardiovascular disease, and malignancy	Pneumonia, car- diac event, thrombosis, pulmonary embolism, multiple organ failure, anemia caused by surgical bleeding, and surgical site infection	N/A
Rommens et al, 2021 ²²	Retrospective	FFP, 362 (type II, 238; type III/IV, 124) Age (years), 81 Gender (men/women), 48/314	Surgical treatment, 138 (percutaneous surgery, 118; ORIF, 20) Age (years), 79 Gender (men/women), 15/123	Non-surgical treatment, 224 Age (years), 82 Gender (men/women), 33/191	Rommens FFP clas- sification, sex, dementia, osteoporosis, diabetes mellitus, pulmonary disease, cardiovascular disease, and malignancy	Pneumonia, urinary tract infection, cardiac event, thrombosis, pulmonary embolism, and pressure ulcer	Hospital mortality and one-year mortality
Saito et al, 2021 ²³	Retrospective	FFP, 64 (type III, 40; type IV, 24) Age (years), 82.6 ± 6.4 Gender (men/women), 6/58	Surgical treatment, 20 (N/A) Age (years), 81.6 ± 5.6 Gender (men/women), 0/20	Non-surgical treatment, 44 Age (years), 83.1 ± 6.7 Gender (men/women), 6/38	Age and sex	Pneumonia, urinary tract infection, cardiac event, and pressure ulcer	One-year mortality
Nuber et al, 2021 ²⁴	Prospective	FFP, 151 (type I, 12; type II, 81; type II, 11; type IV, 47) Age (years), 81.8 ± 2.4 Gender (men/women), 20/131	Surgical treatment, 58 (N/A) Age (years), 79.7 ± 1.9 Gender (men/women), 6/52	Non-surgical treatment, 93 Age (years), 83.1 ± 1.6 Gender (men/women), 14/79	Age and sex	Pneumonia, urinary tract infection, thrombosis, anemia caused by surgical bleeding, and surgical site infection	One-year mortality
FFP: fragility fracture of the pelvis ORIF: open reduction and internal fixation N/A: not available Values (age) are expressed as the mean \pm	ure of the pelvii ion and internal xpressed as the	s fixation mean ± standard deviation or the median.	or the median.				

doi:10.18999/nagjms.85.1.35

Fragility fracture of the pelvis

were excluded due to a lack of comparison (ie, non-surgical cases).^{16,19} No eligible articles were identified from websites, organizations, or the reference lists. Finally, we found 5 published studies²⁰⁻²⁴ involving 1,090 patients with FFP (surgical patients, n = 432; non-surgical patients, n = 658) that were eligible for inclusion in the present systematic review (Table 1).

Risk-of-bias assessment

Table 2 shows the Newcastle–Ottawa Scale scores for the selected studies. The scores ranged from 6 to 7. We therefore considered the present systematic review to be of acceptable quality.

Risk of publication bias

Figure 3 shows a funnel plot of age. All values were inside the range of acceptability and close to the no-effect line. Thus, we considered that this systematic review was associated with an acceptable degree of publication bias.

Study	Selection	Comparability	Outcome	Score
Oberkircher et al, 2021 ²⁰	***	*	**	6
Gericke et al, 2021 ²¹	***		***	6
Rommens et al, 2021 ²²	**	*	***	6
Saito et al, 2021 ²³	**	*	***	6
Nuber et al, 2021 ²⁴	***	*	***	7

Table 2 Assessment of the quality of studies according to the Newcastle–Ottawa Scale for cohort studies




Fig. 3 Funnel plot of age

Main results

Regarding the clinical characteristics, nine factors were identified in this systematic review (Figs. 4 and 5). We found no heterogeneity in FFP type III and IV ($I^2=0\%$, p=0.93), age ($I^2=0\%$, p=0.55), female ($I^2=44\%$, p=0.15), dementia ($I^2=0\%$, p=0.92), osteoporosis ($I^2=16\%$, p=0.28), diabetes mellitus ($I^2=0\%$, p=0.45), pulmonary disease ($I^2=0\%$, p=0.95), cardiovascular disease ($I^2=0\%$, p=0.40), or malignancy ($I^2=0\%$, p=0.52). Therefore, a fixed model was used. FFP type III and IV (OR=8.44; 95% CI 5.99 to 11.88; p<0.00001), younger age (MD=-3.29; 95% CI -3.83 to -2.75; p<0.00001), absence of dementia (OR=0.36; 95% CI 0.23 to 0.57; p<0.0001), and presence of osteoporosis (OR=1.74; 95% CI 1.29 to 2.35; p=0.0003) were associated with the surgical patients. No significant differences existed in the other clinical characteristics of the surgical and non-surgical patients.

Regarding the complications, nine factors were identified in this systematic review (Figs. 6 and 7). We found no heterogeneity in pneumonia ($I^2=0\%$, p=0.90), urinary tract infection ($I^2=9\%$, p=0.35), cardiac event ($I^2=0\%$, p=0.91), thrombosis ($I^2=19\%$, p=0.29), pulmonary

FFP type III/IV

	Surgi	cal	Non-su	rgical		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Gericke et al., 2021	95	168	28	211	47.2%	8.51 [5.15, 14.04]	
Oberkircher et al., 2021	10	48	2	86	5.0%	11.05 [2.31, 52.90]	
Rommens et al., 2021	86	138	38	224	47.8%	8.10 [4.96, 13.22]	
Total (95% CI)		354		521	100.0%	8.44 [5.99, 11.88]	•
Total events	191		68				
Heterogeneity: $Chi^2 = 0.1$	4, df = 2	(P = 0.1)	.93); I ² = (0%			
Test for overall effect: Z =	= 12.22 (F	P < 0.0	0001)				0.02 0.1 i 10 50 Favours [surgical] Favours [non-surgical]

Age (years)

	Su	rgica	al	Non-	surgi	ical		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Gericke et al., 2021	79.4	6.6	168	82.8	7.8	211	13.9%	-3.40 [-4.85, -1.95]	
Nuber et al., 2021	79.7	2	58	83.1	1.6	93	78.7%	-3.40 [-4.01, -2.79]	•
Oberkircher et al., 2021	78.5	7	48	80.7	7.6	86	4.5%	-2.20 [-4.75, 0.35]	
Saito et al., 2021	81.6	5.6	20	83.1	6.7	44	2.9%	-1.50 [-4.65, 1.65]	
Total (95% CI)			294			434	100.0%	-3.29 [-3.83, -2.75]	•
Heterogeneity: $Chi^2 = 2.0$	9, df =	3 (P	= 0.55)	$; I^2 = 09$	6				
Test for overall effect: Z =	= 11.94	(P <	0.0000	1)					-10 -5 0 5 10 Favours (surgical) Favours (non-surgical)

Female

	Surgi	cal	Non-su	rgical		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Gericke et al., 2021	130	168	175	211	60.7%	0.70 [0.42, 1.17]		
Nuber et al., 2021	52	58	79	93	10.9%	1.54 [0.55, 4.25]		
Rommens et al., 2021	123	138	191	224	27.4%	1.42 [0.74, 2.72]		
Saito et al., 2021	20	20	38	44	1.0%	6.92 [0.37, 129.11]		
Total (95% CI)		384		572	100.0%	1.05 [0.73, 1.51]		•
Total events	325		483					
Heterogeneity: Chi ² = 5	.32, df =	3 (P =	0.15); I ² =	= 44%				
Test for overall effect: Z	2 = 0.28 (P = 0.7	(8)				0.01	0.1 1 10 10 Favours [surgical] Favours [non-surgical]

Dementia


	Surgi	cal	Non-su	rgical		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M–H, Fixed, 95% Cl
Gericke et al., 2021	15	168	46	211	53.7%	0.35 [0.19, 0.66]	
Rommens et al., 2021	12	138	46	224	46.3%	0.37 [0.19, 0.72]	
Total (95% CI)		306		435	100.0%	0.36 [0.23, 0.57]	
Total events	27		92				
Heterogeneity: $Chi^2 = 0$				= 0%			0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z	= 4.38 (P < 0.0	0001)				Favours [surgical] Favours [non-surgical]

Fig. 4 Forest plot of the clinical characteristics

Osteoporosis


•										
	Surgi	cal	Non-su	rgical		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	d, 95% CI	
Gericke et al., 2021	72	168	71	211	55.8%	1.48 [0.97, 2.25]		-		
Rommens et al., 2021	88	138	103	224	44.2%	2.07 [1.34, 3.20]				-
Total (95% CI)		306		435	100.0%	1.74 [1.29, 2.35]				
Total events	160		174							
Heterogeneity: $Chi^2 = 1$.18, df =	1 (P =	0.28); I ² :	= 16%				0,5	1	
Test for overall effect: 2	2 = 3.60 (P = 0.0	0003)				0.2	Favours [surgical]	Favours [non-surgi	ical]

Diabetes mellitus



Pulmonary disease

	Surgi	cal	Non-su	rgical		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	
Gericke et al., 2021	24	168	28	211	58.7%	1.09 [0.61, 1.96]	
Rommens et al., 2021	15	138	22	224	41.3%	1.12 [0.56, 2.24]	
Total (95% CI)		306		435	100.0%	1.10 [0.70, 1.73]	
Total events	39		50				
Heterogeneity: Chi ² = 0	.00, df =	1 (P =	0.95); I ² =	= 0%			
Test for overall effect: Z	= 0.42 (P = 0.6	57)				



Cardiovascular disease

	Surgi	cal	Non-su	rgical		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M–H, Fixed, 95% Cl
Gericke et al., 2021	138	168	177	211	57.8%	0.88 [0.52, 1.51]	
Rommens et al., 2021	118	138	185	224	42.2%	1.24 [0.69, 2.24]	
Total (95% CI)		306		435	100.0%	1.04 [0.70, 1.54]	
Total events	256		362				
Heterogeneity: $Chi^2 = 0$.71, df =	1 (P =	0.40); I ² =	= 0%			
Test for overall effect: Z	= 0.17 (P = 0.8	6)				0.2 0.5 1 2 5 Favours [surgical] Favours [non-surgical]

Malignancy

Manghancy									
	Surgi	cal	Non-su	rgical		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl	
Gericke et al., 2021	18	168	17	211	31.7%	1.37 [0.68, 2.75]			
Rommens et al., 2021	31	138	49	224	68.3%	1.03 [0.62, 1.72]			
Total (95% CI)		306		435	100.0%	1.14 [0.76, 1.72]			
Total events	49		66						
Heterogeneity: $Chi^2 = 0$				= 0%			0.2	05 1 2	
Test for overall effect: 2	Z = 0.63 (P = 0.5	53)				0.2	Favours [surgical] Favours [non-surgical]

Fig. 5 Forest plot of the clinical characteristics (continued)

embolism ($I^2=0\%$, p=0.54), pressure ulcer ($I^2=34\%$, p=0.22), multiple organ failure ($I^2=0\%$, p=0.93), anemia caused by surgical bleeding ($I^2=0\%$, p=0.87), or surgical site infection ($I^2=0\%$, p=0.62). According to these results, a fixed model was used. Urinary tract infection (OR=2.06; 95% CI 1.37 to 3.10; p=0.0005), anemia caused by surgical bleeding (OR=4.55; 95% CI 1.95 to 10.62; p=0.0005), and surgical site infection (OR=16.74; 95% CI 3.05 to 91.87; p=0.001) were associated with the surgical patients. No significant differences were observed in the other complications of the surgical and non-surgical patients.

Regarding the outcomes, two factors were identified in this systematic review (Fig. 7). We found no heterogeneity in hospital mortality ($I^2=0\%$, p=0.52). According to these results, a fixed

model was used. In contrast, we found a significant heterogeneity in one-year mortality ($I^2 = 84\%$, p=0.002), and therefore used a random model. No significant differences were observed in the outcomes of the surgical and non-surgical patients.

Pneumonia

	Surgi	cal	Non-su	rgical		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M–H, Fixed, 95% CI
Gericke et al., 2021	6	168	7	211	25.1%	1.08 [0.36, 3.27]	
Nuber et al., 2021	12	58	12	93	30.6%	1.76 [0.73, 4.24]	
Oberkircher et al., 2021	1	48	1	86	2.9%	1.81 [0.11, 29.58]	
Rommens et al., 2021	7	138	12	224	36.4%	0.94 [0.36, 2.46]	_
Saito et al., 2021	1	20	2	44	5.0%	1.11 [0.09, 12.95]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)		432		658	100.0%	1.26 [0.74, 2.15]	► •
Total events	27		34				
Heterogeneity: $Chi^2 = 1.0$	6, df = 4	(P = 0)	.90); I ² =	0%			
Test for overall effect: Z =	= 0.86 (P	= 0.39)				0.01 0.1 İ 10 100 Favours [surgical] Favours [non-surgical]

Urinary tract infection

	Surgi	cal	Non-su	rgical		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Nuber et al., 2021	12	58	12	93	23.6%	1.76 [0.73, 4.24]	
Oberkircher et al., 2021	10	48	6	86	11.0%	3.51 [1.19, 10.37]	
Rommens et al., 2021	36	138	31	224	56.4%	2.20 [1.28, 3.76]	
Saito et al., 2021	0	20	4	44	9.0%	0.22 [0.01, 4.28]	
Total (95% CI)		264		447	100.0%	2.06 [1.37, 3.10]	•
Total events	58		53				
Heterogeneity: Chi ² = 3.2	9, df = 3	(P = 0)	.35); I ² =	9%			0.01 0.1 1 10 1
Test for overall effect: Z =	3.47 (P	= 0.00	05)				Favours [surgical] Favours [non-surgical]

Cardiac event

	Surgi	urgical Non-surgical				Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		
Gericke et al., 2021	2	168	2	211	22.7%	1.26 [0.18, 9.03]		
Oberkircher et al., 2021	1	48	1	86	9.1%	1.81 [0.11, 29.58]		
Rommens et al., 2021	4	138	5	224	48.0%	1.31 [0.35, 4.95]		
Saito et al., 2021	0	20	2	44	20.1%	0.41 [0.02, 9.04]		
Total (95% CI)		374		565	100.0%	1.16 [0.45, 3.02]		
Total events	7		10					
Heterogeneity: $Chi^2 = 0.56$, $df = 3 (P = 0.91)$; $I^2 = 0\%$								
Test for overall effect: $Z = 0.31$ (P = 0.76)								

Thrombosis

	Surgi	Surgical Non-surgical				Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	d, 95% CI	
Gericke et al., 2021	0	168	1	211	30.9%	0.42 [0.02, 10.29]		-		
Nuber et al., 2021	2	58	3	93	51.8%	1.07 [0.17, 6.61]				
Rommens et al., 202	21 4	138	1	224	17.2%	6.66 [0.74, 60.18]		-	•	
Total (95% CI)		364		528	100.0%	1.83 [0.59, 5.72]				
Total events	6		5							
Heterogeneity: Chi ²	= 2.47, df =	2 (P =	0.29); I ²	= 19%			0.02	01	10	
Test for overall effe	ct: Z = 1.04 (P = 0.3	30)				0.02	0.1 Favours [surgical]		כ (Irgical

Pulmonary embolism




Fig. 6 Forest plot of the complications

100

50

50

10

Odds Ratio M-H, Fixed, 95% CI


Favours [surgical] Favours [non-surgical]

0.1

Pressure ulcer

	Surgical		Non-su	rgical	Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
Rommens et al., 2021	11	138	6	224	73.1%	3.15 [1.14, 8.71]	
Saito et al., 2021	0	20	2	44	26.9%	0.41 [0.02, 9.04]	
Total (95% CI)		158		268	100.0%	2.41 [0.97, 6.02]	
Total events	11		8				
Heterogeneity: Chi ² = 1 Test for overall effect: Z				= 34%			0.01 0.1 1 10 100 Favours [surgical] Favours [non-surgical]

Multiple organ failure




Anemia caused by surgical bleeding

Surgica		cal	Non-su	rgical		Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixe	d, 95% CI	
Gericke et al., 2021	3	168	0	211	8.3%	8.95 [0.46, 174.40]				
Nuber et al., 2021	16	58	8	93	85.0%	4.05 [1.60, 10.21]				
Oberkircher et al., 2021	1	48	0	86	6.7%	5.46 [0.22, 136.75]				
Total (95% CI)		274		390	100.0%	4.55 [1.95, 10.62]				
Total events	20		8							
Heterogeneity: $Chi^2 = 0.22$	7, df = 2	(P = 0)	.87); I ² = (0%			0.005	01	10	
Test for overall effect: Z =	3.50 (P	= 0.00	05)				0.005	Favours [surgical]	Favours [non-surg	ical]




-	Surgi	ical	Non-su	rgical		Odds Ratio		Odds	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixe	ed, 95% CI
Gericke et al., 2021	12	168	0	211	36.4%	33.79 [1.99, 574.95]			
Nuber et al., 2021	1	58	0	93	33.3%	4.88 [0.20, 121.78]			-
Oberkircher et al., 2021	2	48	0	86	30.3%	9.30 [0.44, 197.82]		_	-
Total (95% CI)		274		390	100.0%	16.74 [3.05, 91.87]			
Total events	15		0						
Heterogeneity: $Chi^2 = 0.9$	4, df = 2	(P = 0	.62); I ² =	0%			0.002	01	<u>+</u> t
Test for overall effect: Z =	= 3.24 (P	= 0.00	1)				0.002	U.1 Eavours [surgical]	Envoure (r



10

200

200



One-year mortality

	Surgical		Non-su	rgical		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M–H, Random, 95% Cl
Nuber et al., 2021	5	58	28	93	39.5%	0.29 [0.12, 0.70]	
Rommens et al., 2021	11	138	6	224	38.9%	2.98 [1.13, 7.86]	
Saito et al., 2021	0	20	4	44	21.6%	0.24 [0.01, 4.22]	
Total (95% CI)		216		361	100.0%	0.68 [0.10, 4.52]	
Total events	16		38				
Heterogeneity: $Tau^2 = 2$	2.15; Chi ²	= 12.8	39, df = 2	P = 0.0	002); I ² =	84%	0.01 0.1 1 10 100
Test for overall effect: Z	2 = 0.39 (P = 0.6	i9)				Favours [surgical] Favours [non-surgical]



DISCUSSION

This systematic review extensively analyzed the clinical characteristics, complications, and outcomes of FFP patients treated with and without surgery. Nine clinical characteristics were included in the systematic review, four of which were found to be statistically significant: FFP type III and IV, younger age, absence of dementia, and presence of osteoporosis. Nine complications were included in the systematic review, three of which were identified as statistically significant: urinary tract infection, anemia caused by surgical bleeding, and surgical site infection. Two outcomes were included in the systematic review, none of which were found to be statistically significant.

We found that a younger age, the absence of dementia, and the presence of osteoporosis were associated with the surgical patients having FFP. Interestingly, FFP type III and IV itself is reported to be related to younger age,^{14,22} absence of dementia,²² and presence of osteoporosis.²⁸ This may be due to the hypothesis proposed in previous studies^{22,29-31} that a younger age and the absence of dementia, as well as higher mobility, result in higher stresses on the posterior pelvis, leading to more unstable fracture types, especially in patients with osteoporosis. Therefore, we feel that the presence of these clinical characteristics (ie, FFP type III and IV, younger age, absence of dementia, and presence of osteoporosis) is a viable basis which recommends surgical treatment for FFP. Furthermore, the osteological diagnosis and possibly anti-osteoporotic therapy are important in not only non-surgical patients but also surgical patients with FFP. The administration of anti-osteoporosis medications (eg, calcium and vitamin D supplementation, bisphosphonates, and teriparatide) have a positive effect on healing and provide pain relief for FFP,³²⁻³⁵ and the failure to administer anti-osteoporosis therapy could result in additional osteoporotic fractures at secondary sites (eg, hip and vertebrae) within a few years in patients with FFP.³⁶

We found that urinary tract infection, anemia caused by surgical bleeding, and surgical site infection were associated with the surgical patients with FFP. Urinary tract infection may be a complication related to longer length of hospital stay.²¹⁻²³ Indeed, surgical patients with FFP were reported to be associated with longer length of hospital stay than non-surgical patients (surgical patients, mean 18.1–32.7 days; non-surgical patients mean 8.9–23.1 days).²⁰⁻²⁴ Nevertheless, it was reported that sepsis was not associated with the surgical patients with FFP.²¹ Therefore, urinary tract infection should be a minor complication in most cases, if treated appropriately. Anemia caused by surgical bleeding is a surgery-related complication.^{20,21,24} Notably, no significant difference in anemia caused by surgical bleeding was reported between patients who received percutaneous and open procedures for FFP.^{21,37} Surgical site infection is also a surgery-related complication, especially in patients who undergo open reduction and internal fixation for FFP^{21,38}; this may occur when the large wound is contaminated by long-term postoperative bed rest and bed rest excretion. Therefore, minimally invasive surgical treatment (eg, a percutaneous procedure) and getting out of bed early should be prioritized.^{14,21,39-52}

Importantly, other surgery-related complications that have been reported in previous studies could not be analyzed in this systematic review, including: implant malpositioning (2–7%),^{16,21,24} superior gluteal artery damage (1%),⁵³ nerve damage (2–15%),^{21,24} ureteral damage (2%),^{16,53} bowel damage,⁵⁴ wound healing problems,³⁷ instrumentation failure (17–45%),^{55,57} soft tissue irritation requiring implant removal,^{16,38} and cerebrospinal fluid leakage.⁵⁴ Thus, surgeons should keep in mind these surgery-related complications and apply appropriate prophylaxis and follow-up.

There was no significant difference in the rate of hospital and one-year mortality between the surgical and non-surgical patients. Furthermore, a previous study reported no significant difference in two-year or five-year mortality between surgical and non-surgical patients.²² Thus,

the mortality of surgical patients may not be inferior to those of non-surgical patients in the treatment strategy for FFP.

We could not analyze mobility in this systematic review due to the data of the studies. In past studies, the improvement in mobility from admission to discharge in surgical patients was greater than that in non-surgical patients.^{20,22} Further investigations on this topic will be required.

It is important to clarify the differences between our systematic review and other systematic reviews on FFP. Booth et al⁵⁸ searched the literatures on surgical treatment for lateral compression type one FFP in the Young and Burgess classification of pelvic ring injuries.⁵⁹ They concluded that there was insufficient evidence on this topic. Wilson et al¹⁷ investigated the literatures concerning the surgical treatment for FFP patients who failed a brief period of non-surgical treatment. They concluded that surgical treatment for FFP should be considered for FFP patients who failed a brief period of non-surgical treatment, as it significantly improved pain. We first focused on the literatures concerning surgical treatment for FFP with the management protocol described by Rommens et al.¹⁰⁻¹³ We then investigated the clinical characteristics, complications, and outcomes of surgical and non-surgical patients with FFP. As mentioned above, debate is ongoing regarding the treatment strategies for FFP. It is necessary to compare the complications and clinical outcomes of these treatment strategies.

The present systematic review was associated with several limitations. First, a database bias and English language bias were present. Second, this study was limited based on the quality (selection, comparability, and outcome) of the eligible studies, as shown in Table 2. However, the quality of the present systematic review may be acceptable, as the Newcastle-Ottawa Scale scores ranged from 6 to 7. Third, there was a publication bias in this study. Although we searched the relevant unpublished or gray literature, all such studies were excluded. However, the risk of publication bias may be acceptable, since all values were inside the range of acceptability and close to the no-effect line, as illustrated in Fig. 3. Fourth, several surgical techniques of stabilization were used. Notably, the difference of surgical procedures (ie, percutaneous vs open procedures) were reported to be significantly associated with the rate of infections, surgical revisions, and mortality.^{21,37} Accordingly, differences in surgical techniques for stabilization between surgeons, hospitals, and/or literatures may have affected the results. Additional studies on clinical characteristics, complications, and outcomes based on surgical techniques for stabilization are thus warranted. Fifth, the conservative treatments were not unified, which may have affected our result. For instance, pain medication managements varied among the eligible literatures, including "not mentioned",^{21,22} NSAIDs or acetaminophen,²³ and the WHO analgesic ladder.^{20,24} Similarly, there were variations in management for delirium among the eligible literatures, including "not mentioned"²⁰⁻²³ and multidisciplinary care by trauma surgeons, geriatrics, specialists in pain management, physiotherapists, occupational therapists, and speech therapists.²⁴ However, the rehabilitation regimen was similar²⁰⁻²⁴; early mobilization with full weight bearing assisted by physiotherapists under pain control. Finally, and most importantly, current evidence on this topic is still insufficient, possibly due to the fact that the treatment strategy of FFP was first described in 2013,¹¹ so evidence has only recently been accumulating.⁶⁰ Further large-sample, high-quality, and well-documented investigations are necessary to support our findings.

CONCLUSION

The clinical characteristics of FFP type III and IV, younger age, absence of dementia, and the presence of osteoporosis and the complications of urinary tract infection, anemia caused by surgical bleeding, and surgical site infection were associated with the surgical patients with FFP. There were no significant differences in the outcomes between the surgical and non-surgical patients. Our findings may help understand the treatment strategy for FFP described by Rommens et al and be useful for improving the clinical outcomes of FFP patients. The current evidence is still insufficient on this topic, and further large-sample, high-quality, and well-documented investigations are therefore necessary to support our findings.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

- 1 Wollmerstädt J, Pieroh P, Schneider I, et al. Mortality, complications and long-term functional outcome in elderly patients with fragility fractures of the acetabulum. *BMC Geriatr.* 2020;20(1):66. doi:10.1186/s12877-020-1471-x.
- 2 Ueda Y, Inui T, Kurata Y, Tsuji H, Saito J, Shitan Y. Prolonged pain in patients with fragility fractures of the pelvis may be due to fracture progression. *Eur J Trauma Emerg Surg.* 2021;47(2):507–513. doi:10.1007/ s00068-019-01150-0.
- 3 Mendel T, Ullrich BW, Hofmann GO, et al. Progdressive instability of bilateral sacral fragility fractures in osteoporotic bone: a retrospective analysis of X-ray, CT, and MRI datasets from 78 cases. *Eur J Trauma Emerg Surg.* 2021;47(1):11–19. doi:10.1007/s00068-020-01480-4.
- 4 Rommens PM, Hofmann A. Focus on fragility fractures of the pelvis. *Eur J Trauma Emerg Surg*. 2021;47(1):1–2. doi:10.1007/s00068-020-01550-7.
- 5 Osterhoff G, Noser J, Held U, Werner CML, Pape HC, Dietrich M. Early operative versus non-operative treatment of fragility fractures of the pelvis a propensity matched multicenter study. *J Orthop Trauma*. 2019;33(11):e410-e415. doi:10.1097/BOT.00000000001584.
- 6 Rommens PM, Arand C, Hopf JC, Mehling I, Dietz SO, Wagner D. Progress of instability in fragility fractures of the pelvis: an observational study. *Injury*. 2019;50(11):1966–1973. doi:10.1016/j.injury.2019.08.038.
- 7 Buller LT, Best MJ, Quinnan SM. A nationwide analysis of pelvic ring fractures: Incidence and trends in treatment, length of stay, and mortality. *Geriatr Orthop Surg Rehabil.* 2016;7(1):9–17. doi:10.1177/2151458515616250.
- 8 Clement ND, Court-Brown CM. Elderly pelvic fractures: the incidence is increasing and patient demographics can be used to predict the outcome. *Eur J Orthop Surg Traumatol*. 2014;24(8):1431–1437. doi:10.1007/ s00590-014-1439-7.
- 9 Cauley JA. Public health impact of osteoporosis. *J Gerontol A Biol Sci Med Sci.* 2013;68(10):1243–1251. doi:10.1093/gerona/glt093.
- 10 Rommens PM, Ossendorf C, Pairon P, Dietz S-O, Wagner D, Hofmann A. Clinical pathways for fragility fractures of the pelvic ring: personal experience and review of the literature. *J Orthop Sci.* 2015;20(1):1–11. doi:10.1007/s00776-014-0653-9.
- 11 Rommens PM, Hofmann A. Comprehensive classification of fragility fractures of the pelvic ring: recommendations for surgical treatment. *Injury*. 2013;44(12):1733–1744. doi: 10.1016/j.injury.2013.06.023.
- 12 Rommens PM, Wagner D, Hofmann A. Do we need a separate classification for fragility fractures of the pelvis? *J Orthop Trauma*. 2019;33 Suppl 2:S55-S60. doi:10.1097/BOT.00000000001402.
- 13 Rommens PM, Wagner D, Hofmann A. Fragility fractures of the pelvis. JBJS Rev. 2017;5(3):e3. doi:10.2106/ JBJS.RVW.16.00057.
- 14 Hotta K, Kobayashi T. Functional treatment strategy for fragility fractures of the pelvis in geriatric patients. *Eur J Trauma Emerg Surg.* 2021;47(1):21–27. doi:10.1007/s00068-020-01484-0.
- 15 Yoshida M, Tajima K, Saito Y, Sato K, Uenishi N, Iwata M. Mobility and mortality of 340 patients with fragility fracture of the pelvis. *Eur J Trauma Emerg Surg.* 2021;47(1):29–36. doi:10.1007/s00068-020-01481-3.
- 16 Noser J, Dietrich M, Tiziani S, Werner CML, Pape HC, Osterhoff G. Mid-term follow-up after surgical treatment of fragility fractures of the pelvis. *Injury*. 2018;49(11):2032–2035. doi:10.1016/j.injury.2018.09.017.
- 17 Wilson DGG, Kelly J, Rickman M. Operative management of fragility fractures of the pelvis a systematic

review. BMC Musculoskelet Disord. 2021;22(1):717. doi:10.1186/s12891-021-04579-w.

- 18 Banierink H, Ten Duis K, Prijs J, et al. What is the long-term clinical outcome after fragility fractures of the pelvis? - a CT-based cross-sectional study. *Injury*. 2022;53(2):506–513.doi:10.1016/j.injury.2021.09.056.
- 19 Wagner D, Kisilak M, Porcheron G, et al. Trans-sacral bar osteosynthesis provides low mortality and high mobility in patients with fragility fractures of the pelvis. *Sci Rep.* 2021;11(1):14201. doi:10.1038/s41598-021-93559-0.
- 20 Oberkircher L, Lenz J, Bücking B, et al. Which factors influence treatment decision in fragility fractures of the pelvis? – results of a prospective study. *BMC Musculoskelet Disord*. 2021;22(1):690. doi:10.1186/ s12891-021-04573-2.
- 21 Gericke L, Fritz A, Osterhoff G, Josten C, Pieroh P, Höch A. Percutaneous operative treatment of fragility fractures of the pelvis may not increase the general rate of complications compared to non-operative treatment. *Eur J Trauma Emerg Surg.* 2022;48(5):3729–3735. doi:10.1007/s00068-021-01660-w.
- 22 Rommens PM, Boudissa M, Krämer S, Kisilak M, Hofmann A, Wagner D. Operative treatment of fragility fractures of the pelvis is connected with lower mortality. A single institution experience. *PLoS One*. 2021;16(7):e0253408. doi:10.1371/journal.pone.0253408.
- 23 Saito Y, Tokutake K, Takegami Y, Yoshida M, Omichi T, Imagama S. Does surgical treatment for unstable fragility fracture of the pelvis promote early mobilization and improve survival rate and postoperative clinical function? *Eur J Trauma Emerg Surg.* 2022;48(5):3747–3756. doi:10.1007/s00068-021-01729-6.
- 24 Nuber S, Ritter B, Fenwick A, et al. Midterm follow-up of elderly patients with fragility fractures of the pelvis: a prospective cohort-study comparing operative and non-operative treatment according to a therapeutic algorithm. *Injury*. 2022;53(2):496–505.doi:10.1016/j.injury.2021.09.044.
- 25 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1. doi:10.1186/2046-4053-4-1.
- 26 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71.
- 27 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z.
- 28 Graul I, Marintschev I, Hackenbroch C, Palm HG, Friemert B, Lang P. Modified therapy concepts for fragility fractures of the pelvis after additional MRI. *PLoS One*. 2020;15(10):e0238773. doi:10.1371/journal. pone.0238773.
- 29 Wagner D, Kamer L, Sawaguchi T, Richards RG, Noser H, Rommens PM. Sacral bone mass distribution assessed by averaged three-dimensional CT models: Implications for pathogenesis and treatment of fragility fractures of the sacrum. J Bone Joint Surg Am. 2016;98(7):584–590. doi:10.2106/JBJS.15.00726.
- 30 Wagner D, Hofmann A, Kamer L, et al. Fragility fractures of the sacrum occur in elderly patients with severe loss of sacral bone mass. *Arch Orthop Trauma Surg.* 2018;138(7):971–977. doi:10.1007/s00402-018-2938-5.
- 31 Schönenberg D, Guggenberger R, Frey D, Pape HC, Simmen HP, Osterhoff G. CT-based evaluation of volumetric bone density in fragility fractures of the pelvis-a matched case-control analysis. *Osteoporos Int.* 2018;29(2):459–465. doi:10.1007/s00198-017-4307-6.
- 32 Bovbjerg P, Høgh D, Froberg L, Schmal H, Kassem M. Effect of PTH treatment on bone healing in insufficiency fractures of the pelvis: a systematic review. *EFORT Open Rev.* 2021;6(1):9–14. doi:10.1302/2058-5241.6.200029.
- 33 Rommens PM, Arand C, Hofmann A, Wagner D. When and how to operate fragility fractures of the pelvis? *Indian J Orthop.* 2019;53(1):128–137. doi:10.4103/ortho.IJOrtho_631_17.
- 34 Na WC, Lee SH, Jung S, Jang HW, Jo S. Pelvic insufficiency fracture in severe osteoporosis patient. *Hip Pelvis*. 2017;29(2):120–126. doi:10.5371/hp.2017.29.2.120.
- 35 Kasukawa Y, Miyakoshi N, Ebina T, et al. Enhanced bone healing and decreased pain in sacral insufficiency fractures after teriparatide treatment: retrospective clinical-based observational study. *Clin Cases Miner Bone Metab.* 2017;14(2):140–145. doi:10.11138/ccmbm/2017.14.1.140.
- 36 Smith CT, Barton DW, Piple AS, Carmouche JJ. Pelvic fragility fractures: an opportunity to improve the undertreatment of osteoporosis. *J Bone Joint Surg Am.* 2021;103(3):213–218. doi:10.2106/JBJS.20.00738.
- 37 Rommens PM, Hofmann A, Kraemer S, Kisilak M, Boudissa M, Wagner D. Operative treatment of fragility fractures of the pelvis: a critical analysis of 140 patients. *Eur J Trauma Emerg Surg.* 2022;48(4):2881–2896. doi:10.1007/s00068-021-01799-6.
- 38 Santolini E, Kanakaris NK, Giannoudis PV. Sacral fractures: Issues, challenges, solutions. *EFORT Open Rev.* 2020;5(5):299–311. doi:10.1302/2058-5241.5.190064.
- 39 Schmerwitz IU, Jungebluth P, Lehmann W, Hockertz TJ. Minimally invasive posterior locked compression

plate osteosynthesis shows excellent results in elderly patients with fragility fractures of the pelvis. *Eur J Trauma Emerg Surg.* 2021;47(1):37–45. doi:10.1007/s00068-020-01498-8.

- 40 Arduini M, Saturnino L, Piperno A, Iundusi R, Tarantino U. Fragility fractures of the pelvis: treatment and preliminary results. *Aging Clin Exp Res.* 2015;27 Suppl 1:S61-S67. doi:10.1007/s40520-015-0430-4.
- 41 Rommens PM, Wagner D, Hofmann A. Minimal invasive surgical treatment of fragility fractures of the pelvis. *Chirurgia (Bucur)*. 2017;112(5):524–537. doi:10.21614/chirurgia.112.5.524.
- 42 Nakayama Y, Suzuki T, Honda A, et al. Interdigitating percutaneous screw fixation for Rommens type IIIa fragility fractures of the pelvis: technical notes and preliminary clinical results. *Int Orthop.* 2020;44(11):2431–2436. doi:10.1007/s00264-020-04664-0.
- 43 Walker JB, Mitchell SM, Karr SD, Lowe JA, Jones CB. Percutaneous transiliac-transsacral screw fixation of sacral fragility fractures improves pain, ambulation, and rate of disposition to home. *J Orthop Trauma*. 2018;32(9):452–456. doi:10.1097/BOT.00000000001243.
- 44 Kim WY, Lee SW, Kim KW, Kwon SY, Choi YH. Minimally invasive surgical treatment using 'iliac pillar' screw for isolated iliac wing fractures in geriatric patients: a new challenge. *Eur J Trauma Emerg Surg.* 2019;45(2):213–219. doi:10.1007/s00068-018-1046-0.
- 45 Zderic I, Wagner D, Schopper C, et al. Screw-in-screw fixation of fragility sacrum fractures provides high stability without loosening-biomechanical evaluation of a new concept. *J Orthop Res.* 2021;39(4):761–770. doi:10.1002/jor.24895.
- 46 König A, Oberkircher L, Beeres FJP, Babst R, Ruchholtz S, Link BC. Cement augmentation of sacroiliac screws in fragility fractures of the pelvic ring-A synopsis and systematic review of the current literature. *Injury.* 2019;50(8):1411–1417. doi:10.1016/j.injury.2019.06.025.
- 47 Hopf JC, Krieglstein CF, Müller LP, Koslowsky TC. Percutaneous iliosacral screw fixation after osteoporotic posterior ring fractures of the pelvis reduces pain significantly in elderly patients. *Injury*. 2015;46(8):1631– 1636. doi:10.1016/j.injury.2015.04.036.
- 48 Schmitz P, Baumann F, Grechenig S, Gaensslen A, Nerlich M, Müller MB. The cement-augmented transiliacal internal fixator (caTIFI): an innovative surgical technique for stabilization of fragility fractures of the pelvis. *Injury*. 2015;46 Suppl 4:S114-S120. doi:10.1016/S0020-1383(15)30029-2.
- 49 Yoshimura S, Inoue M, Nakajima T, et al. Minimally invasive "crab-shaped fixation" for treating patients with fragility fractures of the pelvis. *Spine Surg Relat Res.* 2021;5(6):425–430. doi:10.22603/ssrr.2020-0213.
- 50 Okazaki S, Shirahama M, Hashida R, et al. Iliac intramedullary stabilization for Type IIIA fragility fractures of the pelvis. *Sci Rep.* 2020;10(1):20380. doi:10.1038/s41598-020-77560-7.
- 51 Schuetze K, Eickhoff A, Dehner C, Blidon A, Gebhard F, Richter PH. Short-term outcome of fragility fractures of the pelvis in the elderly treated with screw osteosynthesis and external fixator. *Eur J Trauma Emerg Surg.* 2022;48(3):2413–2420. doi:10.1007/s00068-021-01780-3.
- 52 Suero EM, Greiner A, Becker CA, et al. Biomechanical stability of sacroiliac screw osteosynthesis with and without cement augmentation. *Injury*. 2021;52(10):2707–2711. doi:10.1016/j.injury.2020.01.043.
- 53 Kang S, Chung PH, Kim JP, Kim YS, Lee HM, Eum GS. Superior gluteal artery injury during percutaneous iliosacral screw fixation: a case report. *Hip Pelvis*. 2015;27(1):57–62. doi:10.5371/hp.2015.27.1.57.
- 54 Pascal-Moussellard H, Hirsch C, Bonaccorsi R. Osteosynthesis in sacral fracture and lumbosacral dislocation. *Orthop Traumatol Surg Res.* 2016;102(1 Suppl):S45-S57. doi:10.1016/j.otsr.2015.12.002.
- 55 Kim JW, Oh CW, Oh JK, et al. The incidence of and factors affecting iliosacral screw loosening in pelvic ring injury. *Arch Orthop Trauma Surg.* 2016;136(7):921–927. doi:10.1007/s00402-016-2471-3.
- 56 Eckardt H, Egger A, Hasler RM, et al. Good functional outcome in patients suffering fragility fractures of the pelvis treated with percutaneous screw stabilization: assessment of complications and factors influencing failure. *Injury*. 2017;48(12):2717–2723. doi:10.1016/j.injury.2017.11.002.
- 57 Herteleer M, Boudissa M, Hofmann A, Wagner D, Rommens PM. Plate fixation of the anterior pelvic ring in patients with fragility fractures of the pelvis. *Eur J Trauma Emerg Surg.* 2022;48(5):3711–3719. doi:10.1007/s00068-021-01625-z.
- 58 Booth A, Ingoe HMA, Northgraves M, et al. Effectiveness of surgical fixation for lateral compression type one (LC-1) fragility fractures of the pelvis: a systematic review. *BMJ Open*. 2019;9(5):e024737. doi:10.1136/ bmjopen-2018-024737.
- 59 Young JW, Burgess AR, Brumback RJ, Poka A. Pelvic fractures: Value of plain radiography in early assessment and management. *Radiology*. 1986;160(2):445–451. doi:10.1148/radiology.160.2.3726125.
- 60 Rommens PM, Hofmann A. The FFP-classification: From eminence to evidence. *Injury*. 2021;S0020-1383(21)00790-7. doi:10.1016/j.injury.2021.09.016.